Pharma

Your Article Summary

See Latest Articles

Dendreon Completes Submission of Biologics License Application for PROVENGE
Dendreon Coproration, 11/03/09

Dendreon Corporation announced that it has completed the submission of the amended Biologics License Application for PROVENGE, the Company's lead investigational product, to the U.S. Food and Drug Administration. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate–resistant prostate cancer. If approved by the FDA, PROVENGE would represent the first product in the new therapeutic class known as active cellular immunotherapies.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09

Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09

AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09

 See all of Drug/Product Approvals